Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 1;109(12):3847-3849.
doi: 10.3324/haematol.2024.286085.

AURKA targeting: a NEAT approach to halt myeloma

Antonio Giovanni Solimando  1 , Cirino Botta  2
Affiliations

AURKA targeting: a NEAT approach to halt myeloma

Antonio Giovanni Solimando et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of a novel therapeutic strategy aimed at inhibiting NEAT1 and AURKA to potentially counteract the progression of multiple myeloma. Disruption of the M/G1 checkpoint prevents the proper assembly of chromatids on the mitotic spindle, thereby arresting the division of multiple myeloma (MM) cells. Intervention at the G1/S checkpoint impedes the activation of growth factors and organelle production, curtailing cell growth. The inhibition of AURKA’s function in mitosis compromises spindle assembly and chromosome segregation. Furthermore, perturbation of the G2/M checkpoint impairs DNA damage repair mechanisms, culminating in the apoptosis of MM cells. This dual targeting represents a significant advancement in the treatment of MM, exploiting the pro-survival and pro-oncogenic properties of NEAT14 and AURKA. AURKA: aurora kinase A; TGF-b: transforming growth factor-beta; ATP: adenosine triphosphate; NEAT1: nuclear paraspeckle assembly transcript 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020;105(10):2358-2367. - PMC - PubMed
    1. Samur MK, Minvielle S, Gulla A, et al. . Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018;32(12):2626-2635. - PMC - PubMed
    1. Puccio N, Manzotti G, Mereu E, et al. . Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma. Haematologica. 2024;109(12):4040-4055. - PMC - PubMed
    1. Taiana E, Bandini C, Favasuli VK, et al. . Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins. Haematologica. 2022;108(1):219-233. - PMC - PubMed
    1. Rosenthal A, Kumar S, Hofmeister C, et al. . A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma. Br J Haematol. 2016;174(2):323-325. - PMC - PubMed

LinkOut - more resources